Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  fulvestrant
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 61 for your search:
Start Over
Phase III Randomized Study of ICI 182780 (Faslodex) versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 11/1999)
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: RPCI-DS-97-29, ZENECA-9238IL/0021, NCI-G98-1412
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000349337, U10CA032102, S0226, CAN-NCIC-MAC7, SWOG-S0226, NCT00075764
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238IL/0048, EFECT, D6997C00048, NCT00065325
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6997C00002, NCT00099437
Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: CDR0000448616, ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: No age specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6997L00002, 9238SW/0001, FACT, NCT00256698
Faslodex Advanced Breast Cancer Local Chinese Study
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6997L00004, NCT00327769
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00475, CDR0000510452, CALGB-40302, U10CA180821, U10CA031946, NCT00390455
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238UK/0005, NCT00944918
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6997L00021, NCT01300351
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
Phase: Phase III
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: D699BC00001, NCT01602380
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBKM120F2302, 2011-005524-17, NCT01610284
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5481023, 2013-002580-26, NCT01942135
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: S1222, NCT02137837
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: GOG-0188, CDR0000068339, NCT00006903
ICI 182780 in Treating Women With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068473, NCCTG-N0032, N0032, NCT00012025
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03148, CDR0000285631, U10CA021115, E4101, ECOG-4101, NCT00057941
Tipifarnib and Fulvestrant as Second-Line Therapy in Treating Postmenopausal Women With Hormone Receptor-Positive Inoperable Locally Advanced or Metastatic Breast Cancer With Progressive Disease After Previous First-Line Endocrine Therapy
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02982, NCI-6205, 6205, N01CM62204, AECM-0104-085, NCT00082810
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238IL/0065, D6997C00003, NCT00093002
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000407580, P50CA090388, P30CA016042, UCLA-0407058-01, NCT00100854
Fulvestrant in Treating Patients With Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: I 53805, RPCI-I-53805, NCT00244998
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 04-075, NCT00146601
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-0494, NCI-2011-03154, NCT00201864
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0141, NCT00234403
Start Over